Israel’s Elgan Pharma (see here previously) has been awarded a 2.36 million euros grant by the European Innovation Council. It will support a Phase III study of its ELGN-GL oral insulin-based formulation that helps the development of a preemie’s gastrointestinal (GI) system.

https://www.timesofisrael.com/israeli-company-nears-final-hurdle-to-okay-insulin-based-preemie-therapy/